Cancer Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

Cancer treatment is the broad term encompassing all medical, surgical, and radiation-based interventions used to eliminate, control, or palliate malignant disease. Modern oncology has transformed cancer from a uniformly fatal diagnosis into a heterogeneous group of conditions — some curable, some chronically manageable, and all requiring individualised, evidence-based treatment planning. Over 18 million new cancer cases are diagnosed globally each year, yet five-year survival rates have improved substantially in most high-income countries due to advances in treatment across all modalities.

The treatment of cancer is directed by the histological type of the malignancy (the cell of origin), molecular and genomic characteristics, clinical stage (extent of disease spread using the TNM classification system), the patient's performance status, and comorbidities. No single treatment modality is universally superior; the most effective outcomes are achieved through multidisciplinary tumour board review, where surgical oncologists, medical oncologists, radiation oncologists, pathologists, and specialist nurses collectively formulate a treatment plan tailored to the individual patient and tumour biology.

The treatment pathway varies significantly by cancer type and stage. Early-stage solid tumours are primarily managed with curative-intent surgery, often combined with adjuvant radiotherapy or chemotherapy to eliminate micrometastatic disease and reduce recurrence risk. Locally advanced cancers frequently require concurrent chemoradiotherapy or neoadjuvant systemic therapy to shrink the tumour before surgery. Metastatic disease is generally not curable (with notable exceptions such as metastatic germ cell tumours and some haematological malignancies) and is managed with life-prolonging systemic therapy, with palliative care integrated from the point of diagnosis.

Cancer treatment addresses malignancies arising from virtually any tissue in the human body. The five most common cancer types globally — lung, colorectal, breast, prostate, and stomach cancers — account for approximately half of all cancer deaths and are the principal focus of treatment guidelines from major oncology organisations including ASCO, ESMO, NCCN, and WHO. Each has a distinct treatment algorithm: non-small-cell lung cancer treatment has been transformed by targeted therapies against EGFR, ALK, ROS1, and KRAS mutations and by PD-1/PD-L1 checkpoint inhibitor immunotherapy; breast cancer is treated according to hormone receptor and HER2 status; colorectal cancer requires assessment for KRAS, NRAS, and BRAF mutations to guide targeted therapy selection.

Haematological malignancies — including acute and chronic leukaemias, lymphomas (Hodgkin and non-Hodgkin), and multiple myeloma — are treated primarily with chemotherapy, immunotherapy, targeted agents, and stem cell transplantation. Rare cancers and those with driver mutations increasingly benefit from tumour-agnostic treatments — therapies approved based on a specific molecular alteration regardless of the organ of origin, such as TRK inhibitors for NTRK fusion-positive tumours or pembrolizumab for MSI-high/dMMR tumours.

All individuals with a confirmed cancer diagnosis are candidates for oncological treatment assessment. The intensity and modality of treatment depend on the cancer type and stage, the patient's performance status (ECOG 0–4 scale), organ function (cardiac, hepatic, renal, pulmonary), age (though chronological age alone is not a contraindication), comorbidities, and — critically — the patient's own goals and preferences following comprehensive informed consent. Multidisciplinary tumour board review ensures that all available treatment options are considered before a treatment plan is recommended.

Some patients may not be candidates for aggressive curative-intent treatment due to advanced age combined with multiple comorbidities, very poor performance status (ECOG 3–4), or patient preference for quality of life over quantity. In these cases, palliative chemotherapy at reduced doses, best supportive care, or clinical trial enrolment may be the most appropriate recommendation. Patients with certain germline mutations (BRCA1/2, Lynch syndrome, hereditary diffuse gastric cancer) require special consideration for prophylactic surgical interventions and family genetic counselling in addition to treatment of the index cancer.

Chemotherapy uses cytotoxic agents that kill rapidly dividing cells, administered intravenously or orally in cycles with rest periods to allow recovery of normal tissues. Platinum-based regimens (cisplatin, carboplatin) remain the backbone of many solid tumour treatments. Taxanes (paclitaxel, docetaxel), anthracyclines (doxorubicin, epirubicin), fluoropyrimidines (5-fluorouracil, capecitabine), gemcitabine, and irinotecan are among the most widely used agents, with regimen selection guided by tumour type, molecular markers, and patient characteristics.

Targeted therapy uses agents that specifically inhibit molecular targets driving tumour growth — including tyrosine kinase inhibitors (imatinib, erlotinib, osimertinib), CDK4/6 inhibitors (palbociclib, ribociclib), PARP inhibitors (olaparib, niraparib), and monoclonal antibodies (trastuzumab for HER2+ breast and gastric cancer, bevacizumab targeting VEGF, cetuximab targeting EGFR). Immunotherapy, particularly immune checkpoint inhibitors blocking PD-1 (pembrolizumab, nivolumab) or CTLA-4 (ipilimumab), has transformed outcomes for melanoma, lung, urothelial, renal, and many other cancers. CAR-T cell therapy offers curative potential for relapsed/refractory B-cell lymphomas and multiple myeloma. Hormonal therapies including aromatase inhibitors, anti-androgens, and GnRH analogues are central to breast and prostate cancer management respectively. Hormone therapies including selective oestrogen receptor modulators, aromatase inhibitors, anti-androgens, and GnRH analogues are central to breast and prostate cancer management respectively. Multidisciplinary tumour boards review all cases to align systemic, surgical, and radiation components of care with the latest evidence-based guidelines and individual patient preferences.

The scope of benefit from cancer treatment ranges from complete long-term cure to significant prolongation of survival and substantial improvement in quality of life. Curative treatment outcomes are exceptional in some cancers: testicular cancer has an overall 5-year survival exceeding 95% even with metastatic disease treated with BEP chemotherapy. Hodgkin lymphoma is curable in over 85% of patients with ABVD chemotherapy plus radiotherapy. Stage I–II colorectal cancer treated surgically achieves 80–90% 5-year survival. Early-stage breast cancer treated with multi-modality therapy achieves 5-year survival exceeding 95%.

For advanced cancers, modern therapies have dramatically improved survival and quality of life. Median overall survival for metastatic non-small-cell lung cancer with PD-L1 expression treated with pembrolizumab has improved from 12 months with chemotherapy to over 26 months in KEYNOTE-024. First-line CDK4/6 inhibitor combinations for hormone receptor-positive metastatic breast cancer have more than doubled median progression-free survival to over 24 months. For chronic myeloid leukaemia, the introduction of imatinib has transformed a disease with 3-year median survival into a chronic condition with near-normal life expectancy.

Chemotherapy-related toxicities are substantial and include myelosuppression (neutropenia, anaemia, thrombocytopenia), nausea and vomiting (controlled in over 80% of patients with modern 5-HT3 and NK1 receptor antagonists), alopecia (hair loss), mucositis, peripheral neuropathy (particularly with platinum compounds and taxanes), cardiotoxicity (with anthracyclines — cumulative dose-dependent risk of cardiomyopathy), nephrotoxicity (cisplatin), and ototoxicity. Febrile neutropenia — fever in the context of a dangerously low neutrophil count — is a potentially life-threatening complication occurring in 20–30% of standard-dose chemotherapy cycles and requires hospitalisation and intravenous antibiotics.

Immune checkpoint inhibitor toxicity differs markedly from chemotherapy: immune-related adverse events can affect virtually any organ system, most commonly causing immune-mediated pneumonitis (3–5%), colitis (1–2%), hepatitis, endocrinopathies (hypothyroidism in 5–10%), and skin reactions. Severe immune-related adverse events require high-dose corticosteroids and may necessitate permanent discontinuation of immunotherapy. Radiation therapy causes acute skin reactions, fatigue, and organ-specific toxicity depending on the treatment field; late effects include secondary malignancy (rare, typically 10–20 years after treatment), radiation fibrosis, and functional impairment of irradiated organs.

Oncological follow-up after completing curative cancer treatment is intensive in the first 2–5 years, when recurrence risk is highest. Surveillance typically involves clinical review every 3–6 months for the first 2 years, every 6 months for years 3–5, and then annually thereafter. Imaging (CT, MRI, or PET-CT depending on cancer type), tumour marker monitoring, and organ-specific tests (PSA for prostate cancer, CA-125 for ovarian cancer, CEA for colorectal cancer) are used to detect recurrence early when salvage treatment is most effective.

Management of treatment-related late effects is an increasingly important component of cancer follow-up. Survivorship clinics address long-term toxicities including chemotherapy-induced peripheral neuropathy, cognitive impairment (chemotherapy-associated cognitive changes, or 'chemo brain'), endocrine dysfunction (hypothyroidism, premature menopause, testosterone deficiency), cardiac toxicity from anthracyclines or trastuzumab, and psychosocial impacts of the cancer experience. Return to work rehabilitation, fertility preservation counselling before treatment (for patients of reproductive age), and health promotion counselling (exercise, smoking cessation, weight management) are integral to comprehensive cancer survivorship care.

Cancer treatment costs in the United States are among the highest in the world, with a full course of chemotherapy ranging from $10,000 to over $300,000 depending on the agents used, and immunotherapy costing $100,000–$250,000 annually. Surgery adds $20,000–$100,000+ depending on complexity; radiotherapy $10,000–$60,000 per course. While most insured US patients have some coverage, out-of-pocket expenses remain a major source of financial toxicity, with cancer patients at significantly elevated risk of bankruptcy.

Medical tourism for cancer treatment at internationally accredited hospitals offers savings of 60–80% versus US costs without compromising clinical quality. India's leading cancer centres — including Tata Memorial Mumbai, Apollo Cancer Institutes, and Medanta — offer surgery, chemotherapy, and radiotherapy at costs typically 70–80% lower than in the United States. A complete course of chemotherapy costs approximately $3,000–$8,000 per cycle versus $15,000–$50,000 in the US; IMRT radiotherapy costs $5,000–$15,000 versus $30,000–$60,000. Thailand (Bumrungrad), Turkey (Acibadem), Singapore (National Cancer Centre), and Germany (leading university hospitals) offer additional high-quality alternatives with excellent English-language services and JCI accreditation.

Complementary and integrative oncology approaches — including acupuncture, mindfulness-based stress reduction, yoga, nutritional optimisation, and herbal medicine — have evidence for improving quality of life and managing treatment-related symptoms such as nausea, fatigue, and anxiety, but do not replace conventional cancer treatments. Patients should always disclose complementary therapy use to their oncologist, as some herbal preparations can interact with chemotherapy or reduce treatment efficacy.

Active surveillance — closely monitoring early-stage cancer without immediate treatment — is an established alternative to upfront treatment for carefully selected patients with low-risk localised prostate cancer, papillary thyroid microcarcinoma, and selected indolent haematological malignancies. Clinical trial participation offers access to novel therapies and represents one of the most evidence-generating alternatives for patients who have exhausted standard treatment options. Precision oncology — tumour genomic profiling to identify actionable mutations and match patients to targeted therapies — is rapidly redefining treatment algorithms, particularly for patients with advanced disease refractory to standard chemotherapy.